A new EU subcommittee is to be set up to advise on matters relating to pharmaceuticals, the European Medicines Agency and public health.
Representatives of the European Parliament’s public health committee (ENVI) have visited the European Medicines Agency to discuss a range of issues including drug shortages, boosting clinical trials, safety monitoring and antimicrobial resistance (AMR).
The 20 February visit came shortly after members of the parliament (MEPs) agreed to set up a new permanent health...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
